Evolution of Devices in Diabetes Management

Abstract

Recent technological advancements in insulin administration and glucose monitoring have allowed patients with diabetes to become increasingly involved in their own care. Devices replacing the traditional vial and syringe, such as insulin pens, are gaining popularity and offer simple and convenient insulin administration. Pen devices are associated with improved dose accuracy, reducing the risk of hypo- or hyperglycemia, and are continually being updated with new safety features in order to optimize their performance. In patients for whom glucose variability remains a problem, continuous subcutaneous insulin infusion via an implanted canula or continuous intraperitoneal insulin infusion via an implanted pump is safe and effective when used correctly, although cost can be a limitation. More accurate retrospective and real-time continuous monitoring devices, which can better detect blood glucose excursions, have become standard components of modern-day diabetes management. The most recent devices have sensor-signaling capabilities with wireless data transmission, leading to reduced time delay and more accurate alerts. Ultimately, though, while self-management remains a critical factor in improving glycemic control at present, human error may undermine even the most accurate treatment interventions. A key long-term goal in diabetes management is, therefore, to develop an automated and accurate closed-loop system for blood glucose monitoring and insulin delivery to better reflect the physiological mechanisms of glucose homeostasis and remove the "human" element. This "artificial pancreas" would offer the most innovative intervention for diabetes management and has the potential to considerably reduce the patient's burden of self-care.

MSC transplantation: a promising therapeutic strategy to manage the onset and progression of diabetic nephropathy

“…While T1DM is due to autoimmune destruction of pancreatic beta cells leading to insulin defi ciency (Cnop et al, 2005), T2DM is a metabolic disorder due to insulin resistance along with impaired insulin secretion (Cnop et al, 2005). Over the past decades, medical advances have substantially improved the management of patients with DM, thereby prolonging their survival (Penfornis et al, 2011). Nevertheless, available treatments do not guarantee a tight glycemic control, since patients do not often adhere well to medical indications.…”

Testing versus guessing blood glucose values: impact on self-care behaviors in type 2 diabetes

“…Blood glucose monitoring has been available as a tool for patients with diabetes for more than 30 years 19,20 . Furthermore, education and resources are available to help people with diabetes learn more about how SMBG can help optimize their overall diabetes management.…”

Progress and challenges in macroencapsulation approaches for type 1 diabetes (T1D) treatment: Cells, biomaterials, and devices

“…Although use of insulin injections and insulin pumps are life-prolonging technologies, they do not mimic real-time secretory patterns of pancreatic β cells nor do they prevent long-term complications (Hinshaw et al, 2013; Penfornis et al, 2011). Medtronic has recently designed a new algorithm, Predictive Low Glucose Management (PLGM), which automatically stops the delivery of insulin when a sensor detects a predetermined low glucose level (Danne et al, 2014).…”